Biotech · Public company · Boston, MA, US
Vor Biopharma Inc.
Ticker VOR · SEC CIK 0001817229
Track this companyFree. Adds Vor Biopharma Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials72 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline6
- TelitaciceptPhase 3 · Generalized Myasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
- TelitaciceptPhase 3 · Primary Sjogren's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- TelitaciceptPhase 3 · Systemic Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026
- MylotargPhase 2 · Leukemia, Myeloid, AcuteClinicalTrials.gov · fetched Nov 12, 2026
- VCAR33Phase 2 · Leukemia, Myeloid, AcuteClinicalTrials.gov · fetched Nov 12, 2026
- VOR33Phase 2 · Leukemia, Myeloid, AcuteClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- Phase 3 Study of Telitacicept in Active Primary Sjögren's DiseasePHASE3 · RECRUITING · started Feb 26, 2026ClinicalTrials.gov NCT07404865 · fetched Nov 12, 2026
- A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)PHASE3 · WITHDRAWN · started Sep 1, 2024ClinicalTrials.gov NCT06456567 · fetched Nov 12, 2026
- A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)PHASE3 · ACTIVE_NOT_RECRUITING · started Jul 17, 2024ClinicalTrials.gov NCT06456580 · fetched Nov 12, 2026
- Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell TransplantPHASE1_PHASE2 · TERMINATED · started Dec 11, 2023ClinicalTrials.gov NCT05984199 · fetched Nov 12, 2026
- A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)PHASE3 · TERMINATED · started Jun 20, 2022ClinicalTrials.gov NCT05306574 · fetched Nov 12, 2026
- A Long-term Follow-up Study of Patients Who Received VOR33TERMINATED · started Apr 15, 2022ClinicalTrials.gov NCT05309733 · fetched Nov 12, 2026
- Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDSPHASE1_PHASE2 · TERMINATED · started Dec 16, 2021ClinicalTrials.gov NCT04849910 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Oct 30, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 7, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 8, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 27, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 18, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 9, 2025 · fetched Nov 12, 2026